rs80357176
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM1BP4BP6
The NM_007294.4(BRCA1):c.994C>T(p.Arg332Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000112 in 1,613,872 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R332Q) has been classified as Likely benign.
Frequency
Consequence
NM_007294.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BRCA1 | NM_007294.4 | c.994C>T | p.Arg332Trp | missense_variant | 10/23 | ENST00000357654.9 | NP_009225.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA1 | ENST00000357654.9 | c.994C>T | p.Arg332Trp | missense_variant | 10/23 | 1 | NM_007294.4 | ENSP00000350283.3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152098Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251342Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135844
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1461774Hom.: 0 Cov.: 34 AF XY: 0.0000124 AC XY: 9AN XY: 727184
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152098Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74288
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:3
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The BRCA1 p.Arg332Trp variant was identified in 1 of 154 proband chromosomes (frequency: 0.006) from individuals with a family history of breast cancer (Tarabeux 2014). The variant was identified in dbSNP (rs80357176) as “with uncertain significance allele, ClinVar (classified as uncertain significance by Invitae, Color, GeneDx, Ambry Genetics and 3 other submitters) and UMD-LSDB (observed 1x). The variant was not identified in LOVD 3.0. The variant was identified in control databases in 2 of 251,342 chromosomes at a frequency of 0.000008 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Other in 1 of 6130 chromosomes (freq: 0.0002), European in 1 of 113,704 chromosomes (freq: 0.000009), while the variant was not observed in the African, Latino, Ashkenazi Jewish, East Asian, Finnish and South Asian populations. The p.Arg332 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA1) | Feb 20, 2004 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Apr 04, 2017 | - - |
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Aug 14, 2023 | This missense variant replaces arginine with tryptophan at codon 332 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in one individual affected with ovarian cancer (PMID: 32850417), three individuals affected with breast cancer (PMID: 35402282, 37335020) and an individual affected with personal or family history of breast cancer (PMID: 35980532). This variant has been detected in a breast cancer case-control meta-analysis in 1/60466 cases and 0/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_006029). This variant also has been reported in an individual age 70 years or older without cancer in the FLOSSIES database (https://whi.color.com/variant/17-41246554-G-A). This variant also has been reported with likelihood ratios of pathogenicity based on co-occurrence with pathogenic co-variant and family history of 1.1391 and 0.4173, respectively (PMID: 31131967). This variant has been identified in 2/251342 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Likely benign, criteria provided, single submitter | curation | University of Washington Department of Laboratory Medicine, University of Washington | Mar 23, 2023 | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 09, 2023 | The p.R332W variant (also known as c.994C>T), located in coding exon 9 of the BRCA1 gene, results from a C to T substitution at nucleotide position 994. The arginine at codon 332 is replaced by tryptophan, an amino acid with dissimilar properties. This alteration has been identified in individuals with personal and/or family histories of breast, ovarian and/or pancreatic cancer (Tarabeux J et al. Eur. J. Hum. Genet. 2014 Apr; 22:535-41; Young EL et al. BMC Cancer, 2018 Jun;18:697; Peixoto A et al. Front Oncol, 2020 Jul;10:1318; Abdel-Razeq H et al. Front Oncol, 2022 Mar;12:673094). This variant was also observed in 1/3251 individuals who met eligibility criteria for hereditary breast and ovarian cancer syndrome (Lerner-Ellis J et al. J Cancer Res Clin Oncol, 2021 Mar;147:871-879). This amino acid position is poorly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 12, 2024 | Variant summary: BRCA1 c.994C>T (p.Arg332Trp) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251342 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.994C>T has been reported in the literature in individuals affected with different types of cancers including but not limited to breast cancer, ovarian cancer, and pancreatic cancer (example: Pereira_2022, Abdel-Razeq_2022, Peixoto_2020, Young_2018) without strong evidence for or against pathogenicity. Somatic occurrence of the variant has also been reported in individuals with colorectal cancer (Yu_2013). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. The following publications have been ascertained in the context of this evaluation (PMID: 35980532, 35402282, 34290354, 31294896, 37335020, 31112341, 32850417, 23942203, 30545397, 29945567, 24951259). ClinVar contains an entry for this variant (Variation ID: 55775). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research | Dec 03, 2015 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 22, 2024 | Observed in individuals with a personal history of breast, ovarian, or pancreatic cancer and in other patients with a personal or family history meeting HBOC testing criteria (PMID: 23942203, 32850417, 29945567, 32885271, 35402282); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 1113C>T; This variant is associated with the following publications: (PMID: 25337278, 15385441, 24951259, 10923033, 23942203, 32850417, 32885271, 29945567, 35980532, 37335020, 32377563, 29884841, 20215511, 15343273, 9926942, 9582019, 11521194, 35402282, 31853058, 31131967) - |
Familial cancer of breast Benign:1
Likely benign, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Feb 09, 2024 | ACMG codes applied following ENIGMA VCEP rules: BP1_STR, BP5_SUP - |
Hereditary breast ovarian cancer syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at